Clinical outcomes of ultrasound‐guided radiofrequency ablation for solitary T1N0M0 papillary thyroid carcinoma: A retrospective study with more than 5 years of follow‐up.

Background: Ultrasound‐guided radiofrequency ablation (RFA) has been used in patients with papillary thyroid carcinoma (PTC) who refuse surgery or active surveillance. However, the long‐term outcomes are still limited. This study aimed to evaluate the clinical outcomes of RFA for solitary T1N0M0 PTC in a large cohort over a more than 5‐year follow‐up period. Methods: This retrospective study included 358 patients with solitary T1N0M0 PTC who were treated with RFA and followed for at least 5 years. The bipolar RFA procedure was performed using hydrodissection technique, transisthmic approach, and moving‐shot technique. The primary outcomes were disease progression, including lymph node metastasis (LNM), recurrent tumor, persistent tumor, and distant metastasis. The secondary outcomes were volume reduction rate, complete disappearance rate, complications, and delayed surgery. Results: During a mean follow‐up period of 75.5 ± 9.7 months, the overall disease progression was 5.0%. The incidence of LNM, recurrent tumor, and persistent tumor was 1.4%, 3.1%, and 0.6%, respectively. There were no significant differences in the disease progression (5.0% vs. 5.5%, p = 1.000), LNM (1.3% vs. 1.8%, p =.568), recurrent tumor (3.3% vs. 1.8%, p =.872), persistent tumors (0.3% vs. 1.8%, p =.284), and 5‐year recurrence‐free survival rates (95.4% vs. 96.4%, p =.785) in the T1a and T1b groups. Volume reduction rate was 100.0 ± 0.3%, with 96.9% of tumors disappearing. No complications occurred. No patients underwent delayed surgery because of anxiety. Conclusions: RFA is an effective and safe alternative for patients with T1N0M0 PTC and can offer a minimally invasive curative option for patients who refuse surgery or active surveillance. Plain Language Summary: During a mean follow‐up period of 75.5 ± 9.7 months, the overall papillary thyroid carcinoma disease progression was 5.0%. The volume reduction rate was 100.0 ± 0.3%, with 96.9% of tumors disappearing.The T1a and T1b groups had similar incidence of disease progression and 5‐year recurrence‐free survival rates. No patients experienced complications or underwent delayed surgery because of anxiety. During a mean follow‐up period of 75.5 ± 9.7 months, the overall disease progression of T1N0M0 papillary thyroid carcinoma was 5.0%. No significant differences were observed in disease progression and recurrence‐free survival rates between the T1a and T1b groups. [ABSTRACT FROM AUTHOR]